Delphi advisor to Pareto Securities in connection with directed share issue

Delphi has assisted Pareto Securities AB in connection with a directed share issue in Xbrane Biopharma AB (publ) through a so-called accelerated bookbuilding, whereby the company receives approximately SEK 240 million before transaction costs. Xbrane Biopharma AB’s share is listed on Nasdaq Stockholm.

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems.

Delphi’s team consisted of Mats Dahlberg, Jenny Lindén and Tove Rodlert.